Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
Mohamed S. Dabour, Mina Y. George, Mary R. Daniel, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 2, pp. 159-182
Open Access | Times Cited: 20
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 18
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry
Pasquale Paolisso, Luca Bergamaschi, Arturo Cesaro, et al.
Diabetes Research and Clinical Practice (2023) Vol. 202, pp. 110766-110766
Closed Access | Times Cited: 40
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
Kyriazoula Chatzianagnostou, Melania Gaggini, Adrian Suman Florentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6218-6218
Open Access | Times Cited: 9
The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes
Antonio Ceriello, Giuseppe Lucisano, Francesco Prattichizzo, et al.
The Lancet Regional Health - Europe (2023) Vol. 31, pp. 100666-100666
Open Access | Times Cited: 22
Emerging role of antidiabetic drugs in cardiorenal protection
Wen-Jia Fu, Jin-Ling Huo, Zi‐Hui Mao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers
Sul A Lee, Leonardo V. Riella
Kidney International Reports (2024) Vol. 9, Iss. 6, pp. 1601-1613
Open Access | Times Cited: 7
Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1–STING axis
Ying Shi, Lili Zhao, Jing Wang, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
SGLT2 inhibitors: how do they affect the cardiac cells
Betül Rabia Erdoğan, Ebru Arioglu‐Inan
Molecular and Cellular Biochemistry (2024)
Closed Access | Times Cited: 6
Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review
Rosalinda Madonna, Filippo Biondi, Mattia Alberti, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116650-116650
Open Access | Times Cited: 5
Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review
Guillaume Mahé, Victor Aboyans, E. Cosson, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Is it time to revise the fighting strategy toward type 2 diabetes? Sex and pollution as new risk factors
Michelangela Barbieri, Francesco Prattichizzo, Rosalba La Grotta, et al.
Ageing Research Reviews (2024) Vol. 99, pp. 102405-102405
Open Access | Times Cited: 5
Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
Lucia Scisciola, Ugo Chianese, Vicky Caponigro, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 12
On the wake of metformin: Do anti-diabetic SGLT2 inhibitors exert anti-aging effects?
Lucia Scisciola, Fabiola Olivieri, Concetta Ambrosino, et al.
Ageing Research Reviews (2023) Vol. 92, pp. 102131-102131
Open Access | Times Cited: 12
Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches
Danielle Rasooly, Alexandre C. Pereira, Joseph Jacob
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2703-2703
Open Access
SGLT2 inhibitor dapagliflozin mitigates skeletal muscle pathology by modulating key proteins involved in glucose and ion homeostasis in an animal model of heart failure
Elena Conte, Paola Imbrici, Giorgia Dinoi, et al.
European Journal of Pharmacology (2025), pp. 177617-177617
Open Access
Cardiometabolic disease management: influences from epigenetics
Natalia Atzemian, S A Mohammed, Ludovica Di Venanzio, et al.
Epigenomics (2025), pp. 1-12
Closed Access
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
Munteanu Madalina Andreea, Swarnkar Surabhi, Răzvan-Ionuț Popescu, et al.
Medicina (2023) Vol. 59, Iss. 4, pp. 742-742
Open Access | Times Cited: 9
Dapagliflozin attenuates the vulnerability to atrial fibrillation in rats with lipopolysaccharide-induced myocardial injury
Xin Zhao, Yating Liu, Xueyu Han, et al.
International Immunopharmacology (2023) Vol. 125, pp. 111038-111038
Open Access | Times Cited: 7
Recent Updates on Epigenetic-Based Pharmacotherapy for Atherosclerosis
Eko Fuji Ariyanto, Ibnu Wijaya, Zaky Alif Pradian, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 1867-1878
Open Access | Times Cited: 2
Co-localization of the sodium-glucose co-transporter-2 channel (SGLT-2) with endothelin ETA and ETB receptors in human cardiorenal tissue
Thomas L. Williams, Rhoda E. Kuc, Anna Paterson, et al.
Bioscience Reports (2024) Vol. 44, Iss. 6
Open Access | Times Cited: 2
Unfolding the complexity of epigenetics in male reproductive aging: a review of therapeutic implications
Ayodeji Folorunsho Ajayi, Mega O. Oyovwi, Goodness Olusayo Olatinwo, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 2
Effects of empagliflozin on right ventricular adaptation to pressure overload
Julie Birkmose Axelsen, Anders Hammer Nielsen-Kudsk, Janne Schwab, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 6
Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
Farah Khaznadar, Ana G. Petrovic, Omar Khaznadar, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6561-6561
Open Access | Times Cited: 5
The latest emerging drugs for the treatment of diabetic cardiomyopathy
Minghao Li, Lin Liu, Chunyu Zhang, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 641-654
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top